Garry Arthur Neil Avalo Therapeutics, Inc. (AVTX) insider trading activity

Garry Arthur Neil is Chief Executive Officer of Avalo Therapeutics, Inc.. Currently has a direct ownership of 47,140 shares of AVTX, which is worth approximately $275,769. The most recent transaction as insider was on Mar 28, 2025, when has been sold 17,787 shares (Common Stock) at a price of $8.46 per share, resulting in proceeds of $150,478. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 47.1K

256.58% 3M change

256.58% 12M change

Total Value Held $275,769

GARRY ARTHUR NEIL Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 28 2025	SELL Payment of exercise price or tax liability	$150,478 $8.46 p/Share	17,787 Reduced 27.4%	47,140 Common Stock
Mar 28 2025	BUY Exercise of conversion of derivative security	-	64,867 Added 49.98%	64,927 Common Stock
Jun 09 2023	BUY Open market or private purchase	$13,680 $3.42 p/Share	4,000 Added 23.23%	13,220 Common Stock
Dec 09 2022	BUY Open market or private purchase	$9,206 $4.42 p/Share	2,083 Added 18.43%	9,220 Common Stock
Dec 10 2021	BUY Open market or private purchase	$6,699 $1.57 p/Share	4,267 Added 4.75%	85,639 Common Stock
Jun 10 2021	BUY Open market or private purchase	$8,418 $2.28 p/Share	3,692 Added 4.34%	81,372 Common Stock
Dec 10 2020	BUY Open market or private purchase	$8,206 $2.28 p/Share	3,599 Added 4.43%	77,680 Common Stock

Also insider at

ARNA

ARENA PHARMACEUTICALS INC Healthcare

Director

CLDX

Celldex Therapeutics, Inc. Healthcare

JATT-WT

JATT Acquisition Corp

Director

GAN